Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune Checkpoint Inhibitor Therapy in Oncology
Sean Tan, Daphne Day, Stephen J. Nicholls, et al.
JACC CardioOncology (2022) Vol. 4, Iss. 5, pp. 579-597
Open Access | Times Cited: 96

Showing 1-25 of 96 citing articles:

Cardiovascular disease and cancer: shared risk factors and mechanisms
Nicholas S. Wilcox, Uri Amit, Jacob B. Reibel, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 9, pp. 617-631
Closed Access | Times Cited: 73
Myocarditis: Etiology, Pathogenesis, and Their Implications in Clinical Practice
Emil Brociek, Agata Tymińska, Andrea Silvio Giordani, et al.
Biology (2023) Vol. 12, Iss. 6, pp. 874-874
Open Access | Times Cited: 28
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
Vincenzo Quagliariello, Irma Bisceglia, Massimiliano Berretta, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1397-1397
Open Access | Times Cited: 25
Cardiovascular disease and lung cancer
Mikhail de Jesus, Anindita Chanda, Titas Grabauskas, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 12
Applications, challenges and future directions of artificial intelligence in cardio‐oncology
Francesco Ravera, Nicolò Gilardi, Alberto Ballestrero, et al.
European Journal of Clinical Investigation (2025) Vol. 55, Iss. S1
Open Access | Times Cited: 1
Cardiac Troponin I and T in ICI Myocarditis Screening, Diagnosis, and Prognosis
Ana Barac, Raymond Wadlow, John F. Deeken, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 5, pp. 804-807
Open Access | Times Cited: 8
Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach
Gillian Murtagh, Christopher R. deFilippi, Qiong Zhao, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 6
Risk Factors for Psoriasis Flares: A Narrative Review
Luca Potestio, Giuseppe Lauletta, Nello Tommasino, et al.
Psoriasis Targets and Therapy (2024) Vol. Volume 14, pp. 39-50
Open Access | Times Cited: 6
Impact of Immunity on Coronary Artery Disease: An Updated Pathogenic Interplay and Potential Therapeutic Strategies
Nicola Laera, Paolo Malerba, Gaetano Vacanti, et al.
Life (2023) Vol. 13, Iss. 11, pp. 2128-2128
Open Access | Times Cited: 16
Circulating Cardiovascular Biomarkers in Cancer Therapeutics‐Related Cardiotoxicity: Review of Critical Challenges, Solutions, and Future Directions
Gillian Murtagh, James L. Januzzi, Marielle Scherrer‐Crosbie, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 21
Open Access | Times Cited: 13
Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment
Weranga Rajapaksha, Riya Khetan, I. R. Johnson, et al.
Frontiers in Drug Delivery (2024) Vol. 4
Open Access | Times Cited: 5
Case Report: Sudden very late-onset near fatal PD1 inhibitor-associated myocarditis with out-of-hospital cardiac arrest after >2.5 years of pembrolizumab treatment
Richard I. Lewis, Katharina Seuthe, Simon Lennartz, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 5
Changes in Physical Activity and Cardiovascular Disease Risk in Cancer Survivors
Wonyoung Jung, In Young Cho, Jinhyung Jung, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 6, pp. 879-889
Open Access | Times Cited: 5
Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
Mohd Nazzary Mamat Yusof, Kah Teik Chew, Nirmala Chandralega Kampan, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15233-15233
Open Access | Times Cited: 12
Severe vs Nonsevere Immune Checkpoint Inhibitor-Induced Myocarditis
Osnat Itzhaki Ben Zadok, Amos Levi, Sanjay Divakaran, et al.
JACC CardioOncology (2023) Vol. 5, Iss. 6, pp. 732-744
Open Access | Times Cited: 11
Systematic Review on the Effectiveness and Outcomes of Nivolumab Treatment Schemes in Advanced and Metastatic Cervical Cancer
Ion Petre, Corina Vernic, Izabella Petre, et al.
Diseases (2024) Vol. 12, Iss. 4, pp. 77-77
Open Access | Times Cited: 4
Clinical Outcomes and Molecular Predictors of Pembrolizumab (Keytruda) as a PD-1 Immune Checkpoint Inhibitor in Advanced and Metastatic Cervical Cancer: A Systematic Review and Meta-Analysis
Lavinia Balan, Anca Maria Cîmpean, Prashant Sunil Nandarge, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1109-1109
Open Access | Times Cited: 4
Immunotherapy in the Treatment of Cancer: Today and Tomorrow
Gökçen Ömeroğlu Şi̇mşek
Current Molecular Biology Reports (2024)
Closed Access | Times Cited: 4
Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune‐related adverse events of immune checkpoint inhibitors
Lishi Lin, Aletta P. I. Houwink, Jolanda M. van Dieren, et al.
Cancer Medicine (2024) Vol. 13, Iss. 12
Open Access | Times Cited: 4
Association of non-high-density lipoprotein to high-density lipoprotein ratio (NHHR) with prognosis in cancer survivors: a population-based study in the United States
Wenxia Xie, Huizhuo Liu, Qiaoxin Lin, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 4
Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: A review of the current knowledge and future directions
Charlotte S. Walmsley, Zachary R. Schoepflin, Charlotte De Brabandt, et al.
Blood Cells Molecules and Diseases (2024) Vol. 110, pp. 102896-102896
Closed Access | Times Cited: 4
Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective Observational Study by Using the Common Data Model
Seok Jun Park, Seungwon Yang, Su-Hyun Lee, et al.
Diagnostics (2025) Vol. 15, Iss. 2, pp. 226-226
Open Access
Mechanisms and Management of Arrhythmias in Cancer Patients
Manyoo Agarwal, Aadhavi Sridharan, Hoang Nhat Pham, et al.
Current Treatment Options in Cardiovascular Medicine (2025) Vol. 27, Iss. 1
Closed Access
Development of Novel Peptide-Based Radiotracers for Detecting FGL1 Expression in Tumors
Yue Xu, Jinyuan Zhang, Donghui Pan, et al.
Molecular Pharmaceutics (2025)
Closed Access
RevCAR-mediated T-cell response against PD-L1-expressing cells turns suppression into activation
Eugenia Crespo, Liliana R. Loureiro, Antonia Stammberger, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top